Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 115 Brain Neoplasms 114 Prostatic Neoplasms 101 Neoplasm Metastasis 79 Carcinoma, Hepatocellular 69 Lung Neoplasms 67 Pancreatic Neoplasms 64 Breast Neoplasms 48 Melanoma 37 Carcinoma, Renal Cell 33 Neoplasms 31 Squamous Cell Carcinoma of Head and Neck 21 Colorectal Neoplasms 20 Liver Neoplasms 19 Glioblastoma 18 Small Cell Lung Carcinoma 14 Head and Neck Neoplasms 14 Sarcoma 11 Kidney Neoplasms 11 Glioma 10 Recurrence 8 Urinary Bladder Neoplasms 7 Radiation Injuries 6 Neuroma, Acoustic 6 Cholangiocarcinoma 6 Adenocarcinoma 6 Uveal Melanoma 5 Uterine Cervical Neoplasms 5 Prostate Cancer Metastatic 5 Ovarian Neoplasms 5

Interventions

Sorafenib 2 nimotuzumab 1 lenvatinib 1 atezolizumab 1 Stents 1 Radiotherapy 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Hematologic Tests 1 Ethiodized Oil 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × HCC × Radiosurgery × Clear all

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡